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Human beings have been exposed to airborne nanosized particles throughout their evolutionary stages, and such exposures
have increased dramatically over the last century. The rapidly developing ﬁeld of nanotechnology will result in new sources of
this exposure, through inhalation, ingestion, and injection. Although nanomaterials are currently being widely used in modern
technology, there is a serious lack of information concerning the human health and environmental implications of manufactured
nanomaterials. Since these are relatively new particles, it is necessary to investigate their toxicological behavior. The objective of
this review was to trace the cellular response to nanosized particle exposure. Therapeutic application of selected nanoparticles
together with their range of toxic doses was also reviewed. Eﬀect of therapeutically used nanoparticles on cell membrane,
mitochondrial function, prooxidant/antioxidant status, enzyme leakage, DNA, and other biochemical endpoints was elucidated.
This paper highlights the need for caution during the use and disposal of such manufactured nanomaterials to prevent unintended
environmental impacts.
Copyright © 2009 A. El-Ansary and S. Al-Daihan. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Nanotechnology involves the creation and manipulation of
materials at nanoscale levels (1–100nm) to create prod-
ucts that exhibit novel properties [1]. The application
of nanotechnology to medicine, known as nanomedicine,
concerns the use of precisely engineered materials at this
length scale to develop novel therapeutic and diagnostic
modalities [2]. Nanomaterials have unique physicochemical
p r o p e r t i e s ,s u c ha su l t r as m a l ls i z e ,l a r g es u r f a c ea r e at o
mass ratio, and high reactivity, which are diﬀerent from bulk
materials (in microscale) of the same composition. These
properties can be used to overcome some of the limitations
found in traditional therapeutic and diagnostic agents.
Nanotoxicology is emerging as an important subdiscipline
of nanotechnology. Nanotoxicology refers to the study of
the interactions of nanostructures with biological systems
with an emphasis on elucidating the relationship between
thephysicalandchemicalproperties(e.g.,size,shape,surface
chemistry, composition, and aggregation) of nanostructures
with induction of toxic biological responses [3, 4].
Many people can get exposed to nanostructures in a
variety of manners such as researchers manufacturing the
nanostructures, patients injected with nanostructures, or
people using products containing nanostructures. In all
cases,there will be unique routes of exposure thatwill dictate
the speciﬁc fate of nanostructures. The overall behavior of
nanostructures could be summed as follows: (1) nanostruc-
turescanenterthebodyviasixprincipleroutes:intravenous,
dermal, subcutaneous, inhalation, intraperitoneal, and oral
[5]; (2) absorption can occur where the nanostructures ﬁrst
interact with biological components (i.e., proteins, cells);
(3) afterward, they can distribute to various organs in the
body and may remain the same structurally, be modiﬁed, or
metabolized [6]; (4) they enter the cells of the organ and
reside in the cells for an unknown amount of time before
l e a v i n gt om o v et oo t h e ro r g a n so rt ob ee x c r e t e d .
Recently, many studies focus on the safety issue of
manufactured nanomaterials to minimize or eliminate their
nanotoxicity even before they are widely used [3, 7–9]. This
paper seeks to provide a comprehensive review of all articles
published on toxicity of therapeutically used nanoparticles2 Journal of Toxicology
together with trials for modiﬁcation of these products
aiming to improve their biocompatibility and minimize their
toxicity.
2. Nanomedicine
Nanomedicine has been deﬁned as the monitoring, repair,
construction, and control of human biological systems
at the molecular level, using engineered nanodevices and
nanostructures[10].Ourbodyisconstructedfromnanoscale
building blocks such as DNA and proteins, which have long
been targeted by the pharmaceutical industry long before
the emergence of nanotechnology [11, 12]. This category of
drugs includes aspirin, cisplatin, and other anticancer agents
as well as much more complex molecules like beta-blockers
and anti-inﬂammatory agents [13]. The diﬀerence between
nanomedicine and conventional drugs is that nanomedicine
is entirely based on small molecule chemistry. It not only
covers the therapeutic agents themselves, but also promise
to combine the abilities to deliver those agents to speciﬁc
regions or tissues in the body, to speciﬁc cells, perhaps to
a speciﬁc location within a cell, and also to make release
of the therapeutic responsive to a physiological condition
and perform speciﬁc task [14]. The increased biological
activity of nanoparticles can be either positive or desirable
(e.g., antioxidant activity, carrier capacity for therapeutic
penetration of blood-brain barrier, and the stomach wall
or tumor pores), dispersed throughout the whole body
including entering the central nervous system, or negative
and undesirable (e.g., toxicity, induction of oxidative stress,
or cellular dysfunction) or a mix of both [3].
Nanoparticles have been found to be distributed to the
colon, lungs, bone marrow, liver, spleen, and the lymphatics
after intravenous injection [15]. Distribution is followed by
rapidclearancefromthesystemiccirculation,predominantly
by action of the liver and splenic macrophages [16]. Clear-
ance and opsonization, the process that prepares foreign
m a t e r i a l st ob em o r ee ﬃc i e n t l ye n g u l f e db ym a c r o p h a g e s ,
occur under certain conditions for nanoparticles depending
on size and surface characteristics [16].
When inhaled, nanoparticles are found to be distributed
to the lungs, liver, heart, spleen, and brain [15]. Nanopar-
ticles are cleared in the alveolar region via phagocytosis by
macrophages facilitated by chemotactic attraction of alveolar
macrophagestothedepositionsite[17,18].Theaveragehalf-
life (t 1/2) for nanoparticles in the respiratory tract is ≈700
days in humans [3].
After intraperitoneal injection, nanoparticles have been
found to cross the transplacental membrane or cross the
peritoneal cavity into uterus. This aﬀected the embryos
cranial development and even caused embryo death [19].
After oral exposure, nanoparticles distribute to the kid-
neys, liver, spleen, lungs, brain, and the gastrointestinal (GI)
tract [15]. Some nanoparticles can pass through the GI tract
and are rapidly eliminated in feces and in urine, indicating
that they can be absorbed across the GI barrier and into
the systemic circulation [15]. However, some nanoparticle
systems can accumulate in the liver during the ﬁrst-pass
metabolism [3].
Contact with nanoparticles through the skin can occur
due to occupational exposure during the manufacturing
of solvents, pesticides, or pharmaceuticals. Skin exposure
to nanoparticles can also occur during nonoccupational
situations from the use of cosmetics and in the intentional
application of topical creams and other drug treatments
[3].
2.1. Nanosized Drug. Many approaches have been developed
to use nanoparticles in the area of biomedical imaging and
drug delivery.Quantum dots (QDs), one of the most well
studied, are nanocrystals that ﬂuoresce in diﬀerent colors
depending on their sizes (e.g., cadmium selenide) [20]. They
typically have a core made of inorganic element, but are
generally coated with organic materials such as polyethylene
glycol to enhance their biocompatibility or attach them to
speciﬁc target molecule like proteins or DNA strands [21].
If the target molecule is an indicator of disease, detection of
that molecule may indicate a higher propensity for disease.
An example is to use nanoparticles to bind to blood clots and
to helpmake clots more visible by ultrasound [22].
Nanoshells, another nanodelivery system that is com-
posed of copolymers, are used in combination with speciﬁc
wavelengths of light and heat technology for cancer therapy.
Gold nanoshells (GNSs) are particularly suitable for use
in the surgical arena as their outer shell is composed of
a commonly used reduced inert gold. When activated by
near infrared light, GNS can raise surrounding temperatures
to levels suﬃcient for cellular ablation. This strategy was
recently used by Stern and Cadeddu [23], for the therapeutic
ablation of urologic malignancies.
Incorporation of cancer-killer genes into nanocapsules
is being tried out. One of the genes being investigated is
the gene elaborate tumor necrosis factor, a protein that is
toxic not only to cancer but also to healthy cells when
injected in large doses. To avoid damage to normal tissue, the
nanocapsule is coated with sensors that target only on tumor
cells.
Deliveryofdrugstothebrainhasalwaysbeenachallenge.
Theuseofnanoparticlestodeliverdrugtothebrainusingthe
pathﬁnder technology is being investigated. This technology
uses nanoparticulate drug carriers in combination with the
novel targeting principle of “diﬀerential protein adsorption”
to cross the blood-brain barrier [24]. As the nanoparticles
are not eﬃciently scavenged by macrophages, the resulting
increase in blood circulation time and hence bioavailability
are expected to extend the duration of controlled system
drug delivery or to improve the prospects for nanoparticles
to reach target sites by extravasation [25]. ‘
Thedeliveryofmagneticnanoparticles(MNPs)toorinto
various cell types has become an area of increasing interest
in the biomedical sciences [26, 27]. Targeted delivery is used
to deliver drugs or genes by attaching them to MNPs and
locally concentrating the resulting complexes in vivo to the
desired locale [28]. Similarly, magnetic hyperthermia, the
local concentration of MNPs and subsequent heating via
magnetic ﬁelds, has shown promise as a potentially viable
cancer therapy [29].Journal of Toxicology 3
Nanosized calcium ﬂuoride (CaF2) that could be used
as F reservoir for more eﬀective F regimens was recently
prepared [30]. The nano-CaF2 c a nb eu s e da sa ne ﬀective
anticaries agent in increasing the labile F concentration in
oral ﬂuid and thus enhances the tooth remineralization. It
can also be very useful in the treatment for the reduction of
dentin permeability.
Nanomedical research could result in an array of new
medical devices. Interesting research projects include use
of nanoelectromechanical device or nanowire ﬁeld-eﬀect
transistor to detect insect baculovirus and single inﬂuenza
viruses, respectively, were conducted [31]. It is hoped that
development of these nanodevices can help physician to
locate the problem areas in the body more precisely. Other
research works involve the use of biochips and microﬂuidic
devices to screen tissues for genetic diﬀerences and to design
genetically targeted drugs [32].
3.Nanotoxicology
While the small size of particles is what makes nanotechnol-
ogy so useful in medicine and industry, it is also one of the
main factors that might make them potentially dangerous
to human health. Research is now showing that harmless
bulk materials opinion is that the smaller the particles are
the more reactive and toxic are their eﬀects.It is because any
intrinsicpropertiesofparticleswilllikelybeemphasizedwith
the increase in surface area per unit mass [33, 34].
The potential risks inherent to any new technology
are recognized. However, the special concern with nan-
otechnology is the unique type of toxicity due to surface
modiﬁcation. Enhanced endocytosis including a potential
for inﬂammatory and prooxidant activity are shown to
be largely dependent on nanoparticles’ surface chemistry
(coating) and in vivo surface modiﬁcations [3, 33]. Increase
in pulmonary toxicity (e.g., inﬂammation, granuloma for-
mation) of carbon nanotubes when compared with that of
thecarbonblackandcarbonylironparticleswasseeninmice
and rats [7, 34].
Oxidative stress caused by free radicals generated by the
interaction of particles with cells may result in cell death.
Evidence of mitochondrial distribution and oxidative stress
response after endocytosis of nanoparticles was noted. It was
suggested that nanoparticles, because of their small sizes,
could act like haptens to modify protein structures, either
by altering their function or rendering them antigenic, thus
raising their potential for autoimmune eﬀects [35].
There is an initial ﬁnding that indicated that gold
nanoparticles might move through a mother’s placenta to
the fetus [36]. Eﬃcient uptake of nanoparticles via the
gastrointestinal tract has also been well documented in oral
feeding studies and gavage studies [37]. All these ﬁndings
indicate that nanoparticles may potentially present problems
with body burdens and it is hypothesized that nanoparticles,
because of their long retention in the body tissues, might
repeat their highly catalytic activity with the host in cascade
[38].
Though nanosilver-based dressing and surgical sutures
havereceivedapprovalforclinicalapplication,andgoodcon-
trol of wound infection is achieved, their dermal toxicity is
stillatopicofconcern.Despitelaboratoryandclinicalstudies
conﬁrming the dermal biocompatibility of nanosilver-based
dressings, several other researchers have demonstrated the
cytotoxicity of these materials [39–44]. Paddle-Ledinek et al.
[45] exposed cultured keratinocytes to extracts of several
types of silver containing dressings. The results showed that
extracts of nanocrystalline coated dressings are among those,
which are the most cytotoxic. Keratinocyte proliferation was
signiﬁcantly inhibited, and cell morphology was aﬀected
[45].
Recently, the identiﬁcation of cytotoxicity of nanopar-
ticles toward mammalian germline stem cells has aroused
great concern over the biosafety of nanomaterials [46]. In
their study, they used a cell line with spermatogonial stem
cell characteristics to test in vitro toxicity of several types
of nanoparticles. The results showed that of all the tested
materials (Ag, MoO3, and Al), silver nanoparticles were
the most toxic with manifestations like drastic reduction
of mitochondrial function, increased membrane leakage,
necrosis, and induction of apoptosis. The ﬁndings are of
signiﬁcantpracticalimplicationsbecausesilvernanoparticles
are now able to access human sperms via a variety of
commercialized products like contraceptive devices and
maternalhygieneitems.Basedonthis,fertilityproblemsmay
occur. In addition, as a fair extrapolation, another question
emerged: what they will do to egg cells?
Liver appears to be a major accumulation site of circula-
tory silver nanoparticles [47]. Like germ line stem cells, sim-
ilar patterns of cytotoxicity of silver nanoparticles (decrease
of mitochondrial function, LDH leakage, and abnormal cell
morphologies) were observed with in vitro BRL 3A rat liver
cells, but to a lesser extent [1]. In another study by the
same researchers, a neuroendocrine cell line (PC-12 cells)
was exposed to silver nanoparticles as a control against Mn
nanoparticles and Mn2+ [48]. Experimental results showed
that silver nanoparticles were toxic to mitochondria than to
Mn and Mn2+.
All of these ﬁndings are of importance because consider-
able amount of silver could be detected in rat brain following
inhalation of silver nanoparticles [47]. The neurological
toxicity of silver is not clinically ascertained, however, several
seizures cases have been related to exposure to silver or silver
compounds [49]. Thus, mitochondria seem to be sensitive
targets of cytotoxicity of silver nanoparticles. However, the
mechanism of silver nanoparticles action on mitochondria is
yet to be elucidated. In the study, with BRL 3A liver cell line,
depletionofglutathione(GSH)levelandincreasedROSwere
found in association with mitochondrial perturbation, sug-
gesting thatoxidative stressmightmediate thecytotoxicity of
silver nanoparticles. Based on these ﬁndings, a preliminary
impression can be formed that silver nanoparticles may
interact with proteins and enzymes with thiol groups within
mammalian cells. These proteins and enzymes like glu-
tathione, thioredoxin, SOD, and thioredoxin peroxidase are
key components of the cell’s antioxidant defense mechanism
which is responsible to neutralize the oxidative stress of
ROS largely generated by mitochondrial energy metabolism.
As these eﬀects of Ag+ could be completely blocked by4 Journal of Toxicology
sulfhydryl reagents as GSH, the surface modiﬁcation of
silver nanoparticles by phosphoryl disulﬁdes was eﬀective in
improving silver biocompatibility and intracellular uptake
[50]. They prepared the phospholipid derivatives containing
disulﬁde groups to modify silver nanoparticle surfaces. By
adding sodium borohydride to reduce both disulﬁde bonds
ofthederivativesandsilverionsimultaneously,thegenerated
thiol group can be reacted with newborn silver atoms imme-
diately to generate nanoclusters. The assemblies consisted of
either phosphorylcholine (PC) or Phosphorylethanolamine
(PE) head groups, which made the silver clusters bio-
compatibile. In cell culture tests, the surfaces modiﬁed
nanoparticles were internalized into platelet and ﬁbroblast
cells in a short period of incubation without harming the
cells.
The study of Pisanic II et al. [51] indicates that even tem-
porary exposure to Fe2O3 magnetic nanoparticles (MNPs)
results in a dose-dependent reduced ability rat pheochro-
mocytoma growing neuron cell line PC12 to respond to
nerve growth factor (NGF). PC12 cells exposed to diﬀerent
doses of Fe2O3 MNPs show reduced viabilities, increased
cytoskeletal disruption, decreased intracellular contact, and
diminished ability to form mature neuritis in response to
NGF exposure as compared to control cells (Figure 1). This
may have signiﬁcant implication for in vivo phenotypic
dependent in vitro uses of Fe2O3 in general. Wiwanitkit
et al. [52] demonstrated in a preliminary small study that
the motility of spermatozoa was aﬀected by the presence
of gold nanoparticles. They noted that gold particles can
penetrate sperm cells, which could result in fragmentation.
The possible spermatotoxicity of gold in industrial use
has been reported elsewhere as a cause of male sterility
[53].
3.1. Ultrahigh Reactivity Provokes Nanotoxicity. Because the
nanosize/surface area of the nanosubstance is directly cor-
related to many essential characteristics like surface proper-
ties, chemical reactivity, physical absorption ability, and so
forth, all these factors strongly dominate nanotoxicological
behavior in vivo [54]. The study of Chen et al. [43] on the
acute oral toxicity of copper particles has shown a signiﬁcant
correlation with its size distribution. With the particle size
reducing from 17μm (particle number: 44 per μg; surface
area3.99×102 cm2/g)to23.5nm(particlenumber:1.7×1010
perμg;surfacearea2.95×102 cm2/g),LD50 ofcopperparticle
sharplyincreasesfrom>5000mg/kg(nontoxic)to413mg/kg
(moderately toxic) based on the Hodge and Sterner scale.
For identical chemical composition, why do the nanocopper
particles possess unique biobehavior (nanotoxicity) in vivo
comparing to those in bigger size (in microscale)? Looking
for answer for this question may provide an insight into
nanotoxicity reducingorelimination. Theyexplainedthis on
the basis that nanocopper particles may not compromise the
mice directly. The nanocopper retained in gastric lumen can
continuouslyreactwiththesecretedacidjuice.Thedepletion
of H+ results in metabolic alkalosis because the HCO3
generated during production of gastric acid will return to
the circulation resulting in the formation of large quantities
of sodium bicarbonate which increase the arterial blood pH
(Figure 2).
The elevation of blood pH motivates a set of com-
pensatory eﬀects: (a) a respiratory compensation which is
limited[55],(b)renalcompensationstartsrelativelylaterbut
can sustain for a long time (several days) [55, 56]. However,
a series of abnormalities were found in the pathological
examination such as swollen glomerulus, dwindling in
lumen Bowman’s capsules, and being signs of glomeru-
lonephritis. The renal dysfunction may largely weaken renal
compensation in nanocopper group and deteriorate the
metabolic alkalosis.
It is reported that copper ions ingested are metabolized
in liver and excreted via urine [57]. If the intake of copper
exceeds the range of the tolerance, it would cause toxic
eﬀects to hepatic and renal tissues, which is consistent with
the ﬁnding of Meng et al. [58] that nanocopper possesses
extremely high bioavailability, hence, the original safety limit
maybemodiﬁedtomuchlowerlevel.Basedontheseﬁnding,
we can suggest that nano-and microcopper exhibit diﬀerent
biological behaviors in vivo via oral exposure routine. In
terms of nanocopper particle, both copper overload and
metabolic alkalosis contribute to their grave toxicity.
High chemical reactivity of Ag nanoparticles was
observed in the reaction with hydrochloric acid: Ag
(nanoparticles) + HCl →AgCl + H2; the reaction product
silver chloride was characterized by X-ray powder diﬀraction
to give a direct evidence for the reaction which has been
proved impossible for the bulk Ag [59].
The microscale titanium dioxide (TiO2), widely used
in pharmaceutical and cosmetics industries, is considered
as biologically inert [60]. Such that, there was no obvious
lung toxicity in rats when a single instilled dose of TiO2
was 5mg/rat or 50mg/kg [61]. However, many studies have
demonstrated that when TiO2 particles size decreased to
nanoscale dimension, they could produce more pulmonary
toxicity than their bulk counterparts [62–65]. In a com-
parative study done by Li et al. [66], the acute pulmonary
toxicity induced by 3 and 20nm TiO2 was investigated
through measurement of selected biochemical parameters in
bronchoalveolar lavage ﬂuid (BALF). At 3-day postexposure,
the 3nm TiO2 induced signiﬁcant increase of albumin,
alkaline phosphatase (ALP), and acid phosphatase (ACP)
concentrations in high-dose group (40mg/kg) and also
induced signiﬁcant increase of ALP and ACP concentrations
in mid-dose group (4mg/kg), but did not induce signiﬁcant
increase of total protein and LDH concentrations in any dose
group. On the other hand, 20nm TiO2 induced signiﬁcant
increase of all biochemical parameters in high- and mid-
dose groups. At 3-day postexposure, both TiO2 particles did
not induce obvious pulmonary toxicity in their low-dose
(0.4mg/kg) groups as evidence of no signiﬁcant increase
of all biochemical parameters. The pH values of 3nm
TiO2 particles colloid were 5.38 ± 0.12, 4.55 ± 0.07, and
4.42 ± 0.13 at concentrations of 0.1, 1, and 10mg/mL,
respectively, while at the corresponding concentration, the
pH values of 20nm TiO2 particles suspension were 5.5 ±
0.19, 4.64 ± 0.11, and 3.75 ± 0.04, respectively. They
reported that pH value of TiO2 particles in medium,Journal of Toxicology 5
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Figure 1: (a) Number of intracellular contacts and (b) formation of neuritis in nano-Fe2O3 treated PC12 nerve cells.
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Figure 2: Mechanism of metabolic alkalosis induced by nanocopper ion.
other than particle size, surface area, and aggregation, plays
important role in aﬀecting TiO2 nanoparticles pulmonary
toxicity.
The potentiated toxicity of nanoscale vanadium oxide
(V2O3) compared to bulk material is demonstrated in
human endo- and epithelial lung cells and might be due to
the higher catalytic surface of the particles [60]. Reduction
in cell viability is almost ten times stronger and starts
with the lowest concentrations of “nanoscaled” material
(10μg/mL). Vanadium oxide leads to an induction of heme
oxygenase1(HO-1)inadose-dependentmannerinECV304
cells, whereas a reduction in protein levels can be observed
for the epithelial cells (A549). Lipid peroxidation can be
observed also for “nanoscaled” vanadium oxide to a much
stronger extent in macrophages (RAW cells) than for bulk
material. The observed eﬀects cannot only be explained
by oxidation from V2O3 to V2O5 as there are signiﬁcant
diﬀerences between the novel nano-vanadium and all used
bulk materials (V2O3 and V2O5). It appears rather to be a
nanoeﬀect of a high surface reactivity, here coupled with
a yet unknown toxicity potentiating eﬀect of a technically
important catalyst.
4. Protein-NanoparticleInteractions
Within the medical device community, it is now well
accepted that material surfaces are modiﬁed by the adsorp-
tion of biomolecules such as proteins in a biological
environment [67, 68], and there is some consensus that
cellular responses to materials in a biological medium
reﬂect the adsorbed biomolecule layer, rather than the
material itself. However, the importance of the adsorbed
protein layer in mediating interactions with living systems
has been slower to emerge in the case of nanoparticle-
protein interactions. The key role of protein-nanoparticle
interactions in nanomedicine and nanotoxicity has begun
to emerge recently with the development of the idea of
the nanoparticle-protein “corona”. This dynamic layer of
proteins (and other biomolecules) adsorbs to nanoparticle
surfaces immediately upon contact with living systems. The
composition of the protein corona at any given time will
be determined by the concentrations of the over 3700
proteins in plasma [69] and the kinetic on and oﬀ rates
(or equilibrium binding constants) of each protein for the
particular nanoparticle. This corona may not immediately6 Journal of Toxicology
reach equilibrium when exposed to a biological ﬂuid.
Proteins with high concentrations and high association rate
constants will initially occupy the nanoparticle surface, but
may also dissociate quickly to be replaced by proteins of
lower concentration, slower exchange, and higher aﬃnity.
Thus, the protein corona is the biological identity of a
nanoparticle, as it is what the cell “sees” and interacts
with. Functional changes of proteins of such complexes
may be another mechanism by which particularly small
nanoparticle, with their large surface area as a binding
interface, may induce protein mal-functioning, which may
lead to the pathogenesis and adverse health eﬀects [70].
Survey of the literature on nanoparticle-protein binding
shows that the vast majority of nanoparticle types studied,
so far, bind apolipoproteins [68]. At ﬁrst sight, this is
surprising result and quite distinct from that for a ﬂat
surface. However, the fact that apolipoproteins are known to
be involved in lipoprotein complexes, which themselves have
sizes on the nanoscale ranging from 100nm (chylomicron)
to10nm(high-densitylipoprotein),maymeanthatthereare
speciﬁc size-dependent interactions that drive the binding
of apolipoprotein to nanoparticles. This is interesting from
the point of view of nanoparticle interaction with cells, as
lipoprotein complexes are involved in the general cellular
processesofcholesterolmetabolism [2].Thus,therearemul-
tiple receptors for apolipoprotein complexes at cell surfaces
that nanoparticles with surface-adsorbed apolipoproteins
can potentially exploit to enter cells [71]. If we consider
the issues of nanoparticle transport and fate in animals and
humans, then it is also relevant that apolipoprotein E has
been found to associate to some nanoparticles [67]. This has
potentially signiﬁcant consequences for neurotoxicity and
the development of neurotherapies, as apolipoprotein E is
known to be involved in traﬃcking to the brain [71].
The ﬁrst reports of the direct biological inﬂuence of pro-
teins adsorbed to nanoparticles are now emerging. Single-
walled carbon nanotubes (SWNTs) and 10nm amorphous
silica coated with albumin have been shown to induce anti-
inﬂammatory responses in macrophages, measured as inhib-
ited induction of cyclooxygenase-2- (Cox-2) by lipopolysac-
charide under serum-free conditions [72]. Blocking the
adsorption of albumin by precoating the nanoparticles
with nonionic surfactant (Pluronic F127) also inhibits the
anti-inﬂammatory properties of the nanoparticles. These
observations suggest an important role for the adsorbed
proteins in modulating the uptake and toxicity of SWNTs
and nanosized amorphous silica [72]. However, as these
studies were conducted under serum-free conditions, it
is unclear whether the albumin would remain bound to
nanoparticles under competitive binding conditions, such as
those occur in plasma or in a cellular milieu. The interaction
between human adult hemoglobin (Hb) and bare CdS QDs
dramatically alters the conformation of Hb and decreasing
the α-helix content of the secondary structure from 72.5% to
60.8%. Raman spectra results indicate that the sulfur atoms
of the cysteine residues form direct bonds on the surface
of the CdS QDs [73]. Functionalization of nanoparticles
surfaces with peptides is increasingly being used to control
the interaction of nanoparticles with proteins [69].
5. Discussion
Nanotoxicology refers to the biokinetic evaluation of engi-
neered nanostructures and nanodevices. The need for this
area of investigations became apparent after the intensive
expansion of nanotechnology, which in the last two decades
has been widely used in the pharmaceutical industry,
medicine, and engineering technology [74, 75]. Particle
toxicology and the consequent adverse health eﬀects of
asbestos ﬁbers and coal dust serve as a historical reference
points to the development of nanotoxicological concepts.
In the area of medicine, nanomedicine has been deﬁned
as the monitoring, repair, construction, and control of
human biological systems at the molecular level, using engi-
neered nanodevices and nanostructures [10]. Macrophages
as specialized host defense cells, endothelium as thin spe-
cialized epithelial cells that line the inner surface of lymph
vessels and blood vessels serve as gate keeper to control
passage of materials together, and tumors are the most
common targets of nanoparticles. Within these biological
targets, nanoparticles favor the formation of prooxidants
especially under exposure to light, ultraviolet light, or
transition metals; thereby destabilizing the balance between
the production of reactive oxygen species (ROS) and the
biological system’s ability to detoxify or repair the system
[74,75].ROScanalsobeproducedbytheNADPHoxidasein
phagocytic cells as target of nanoparticle devices. Nanopar-
ticles can modify mitochondrial function as well as cellular
redox signaling. Oxidative stress induced by nanoparticles is
reported to enhance inﬂammation through upregulation of
redox-sensitive transcription factors including nuclear factor
kappa B (NFkB), activating protein (AP-1), and extracellular
signal regulator kinases (ERK) C-Jun, N-terminal kinases
JNK, and p38 mitogen-activated protein kinases pathways.
Figure 3 summarizes the most important recorded toxic
eﬀects of therapeutically used nanoparticles reviewed in the
present paper.
6. Concluding Remarks
(1) Nanotechnology is growing at an exponential rate and
will undoubtedly have both beneﬁcial and toxicological
impact and consequences on health and environment.
(2) As a result of their properties, nanomaterials diﬀer
substantially from those bulk materials of the same compo-
sition,allowing them to perform exceptional feats of conduc-
tivity,reactivity, and optical sensitivity. Possible undesirable
resultsof these capabilities are harmful interactions with
biologicalsystems with the potential to generatetoxicity.
(3) Development of new techniques to show accurate
correlationsbetweeninvitroandinvivostudiesisimperative
to accurately portray nanoparticle eﬀects. Moreover, toxicity
studies are critical to establish the full in vivo potential of
nanomedicine. Understanding the physiochemical, molecu-
lar, and physiological processes of nanoparticles is important
for nanomedicine to become a reliable and sustainable
treatment modality.
(4) In the future, nanoparticles could be classiﬁed in
terms of their biomolecule corona which mediates theirJournal of Toxicology 7
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Figure 3: A summary of the most important recorded toxic eﬀects of therapeutically used nanoparticles reviewed in the present paper.
interaction with cellular machinery. This would represent a
truly new paradigm in the ﬁeld of nanoscale toxicology and
in the design of safe nanocarriers for nanomedicine.
(5) With this new opportunity to utilize the unique
properties of nanoparticles for research, industry, and
medicine, there is a responsibility to test and optimize these
new nanomaterials early during the development process to
eliminate or ameliorate identiﬁed toxic characteristics.
(6) The rapid commercialization of nanoparticles
requires focused environmental, health, and safety research,
meaningful and open discussion of broader societal impacts
and urgent oversight.
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